CD6 is a target for cancer immunotherapy

Limitations of checkpoint inhibitor cancer immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Since CD318, a novel CD6 ligand, is associated with the aggressiveness and metastatic potential of human cancers, we tested the effect of an anti-CD6 monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruth, Jeffrey H., Gurrea-Rubio, Mikel, Athukorala, Kalana S., Rasmussen, Stephanie M., Weber, Daniel P., Randon, Peggy M., Gedert, Rosemary J., Lind, Matthew E., Amin, M. Asif, Campbell, Phillip L., Tsou, Pei-Suen, Mao-Draayer, Yang, Wu, Qi, Lanigan, Thomas M., Keshamouni, Venkateshwar G., Singer, Nora G., Lin, Feng, Fox, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021120/
https://www.ncbi.nlm.nih.gov/pubmed/33497367
http://dx.doi.org/10.1172/jci.insight.145662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021120/
https://www.ncbi.nlm.nih.gov/pubmed/33497367
http://dx.doi.org/10.1172/jci.insight.145662

Ejemplares similares